Roche develops new serology test to detect COVID-19 antibodies

Basel, 17 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the development and upcoming launch of its Elecsys ® Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes the COVID-19 disease. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms. ³ Additionally, the test can support priority screening of high risk groups, such as healthcare workers, food supply workers who might already have developed a certain level of immunity and can continue serving and/or return to work. Once we understand more about the immunity of COVID-19, it could also help society return faster to normality. Severin Schwan, CEO Roche Group: “Following the launch of our high-volume PCR test in mid-March to detect active infection of the disease, we are now going to launch a new antibody test in early May. Every reliable test on the market serves its purpose for healthcare systems to help us overcome this pandemic. Roche is collaborati ng closely with health authorities and ramping up production to ensure fast availability of the test globally.”“Roche is deeply committed to supporting the global response to the COVID-19 pandemic,” said Thomas Schinecker, CEO Roche Diagnostics. " Timely availability and fast access to reliable, high quality tests are essential for heal...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news